hVIVO has been at the forefront of running human challenge studies for more than 20 years and has built up one of the most comprehensive, multi-parametric bio and databanks ever created for infectious diseases
The Disease in Motion platform has multiple infectious disease applications that are applicable to a wide variety of end users including big tech, wearables, pharma and biotech companies.
RE: Launch of Disease in Motion platform9 Apr 2021 08:28
We have ambitions for one of the spin-outs to be IPO'd on AIM and then cross-listed on Nasdaq OTC and I'll be keeping a hands-on role there as Executive Chairman."
Finally he stated: "I have set a target for us to get to of 1 billion dollars ((roughly £750M) between Open Orphan and the spin-offs."